Precipio, Inc.
Precipio, Inc. is a U.S.-based healthcare biotechnology company focused on cancer diagnostics. It develops and commercializes diagnostic products and pathology services through its clinical laboratory operations and product division.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueClinical laboratory testing and diagnostic pathology services performed through the New Haven CLIA lab.
Cancer-focused laboratory products sold directly and through distributors.
Products
Reported · share of revenue- Service Revenue Net88.7 %
- Products11.3 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Precipio sells to laboratories, pathology practices, and healthcare organizations that need cancer diagnostic testing or related products. Its product business also reaches labs through national distributors, while its clinical lab services are used by patients and referring providers seeking pathology analysis.
Buy diagnostic products and consumables for use in laboratory workflows and testing
Use pathology services for cancer-related diagnostic interpretation and testing
Purchase and distribute products to reach laboratory customers nationwide
Receive pathology services through the company’s clinical laboratory operations
Strategy
Precipio’s strategy is built around using its own clinical laboratory as a development and validation engine for new diagnostic products. It also relies on distributor partnerships to broaden access to laboratories and accelerate commercialization of its cancer diagnostics portfolio.
Internal testing and validation reduce development time and improve product fit for real workflows
National distributors extend reach into laboratory customers without building a large direct sales footprint
The company’s product pipeline is centered on solving diagnostic accuracy problems in oncology
Geography
Precipio is based in the United States and operates primarily through its New Haven, Connecticut clinical laboratory. The company states that it mainly serves the U.S. market, while its products may also be sold in other countries through global healthcare distributors.
Risks
Precipio faces execution risk from dependence on reimbursement, billing operations, and access to capital, which are important for a company combining services and product development. It is also exposed to regulatory, trade, and tariff changes, as well as clinical and product-development risks typical of diagnostics businesses.
- Liquidity and financing dependenceImpact: CriticalLikelihood: Low
The business needs external funding and revenue growth to support operations and obligations
Exposure: Company-wide
- Billing and reimbursement disruptionImpact: High
Pathology services depend on third-party billing systems and payer remittances, so interruptions can delay cash collection
Exposure: Pathology services
- Regulatory and reimbursement riskImpact: High
Clinical laboratory and diagnostic businesses are sensitive to healthcare regulation and payer policy
Exposure: U.S. diagnostics and pathology
- Trade and tariff exposureImpact: MediumLikelihood: Medium
Imported goods or supplier inputs may become more expensive under tariff changes
Exposure: Laboratory products supply chain
- Product development and validation riskImpact: Medium
New diagnostics require specimens, skilled staff, and successful validation before commercialization
Exposure: Pipeline products
Accounting
Judgemental itemsPathology service revenue includes estimates for expected reimbursement and over-collections, which can change reported sales
Impact: Affects quarterly service revenue and receivables
Billing collections depend on payer and patient remittances, so credit estimates affect net service revenue
Impact: Affects reported net sales
Management must assess whether the company can continue operations and meet obligations
Impact: Affects financial statement presentation and risk disclosure
Disruptions in claims processing can create temporary funding, repayment, and write-off items
Impact: Affects other liabilities and cash flow
Similar listed companies
Publicly listed companies with a comparable business focus.
Precigen, Inc
PGEN · Pharmaceutical Preparations
Inovio Pharmaceuticals, Inc
INO · Pharmaceutical Preparations
INOVIO Pharmaceuticals is a clinical-stage biotechnology company developing DNA medicines designed to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases.
Prelude Therapeutics Inc
PRLD · Pharmaceutical Preparations
LeonaBio, Inc.
LONA · Biological Products, (No Diagnostic Substances)
IO Biotech, Inc.
IOBTQ · Pharmaceutical Preparations
Veracyte, Inc
VCYT · Services-Medical Laboratories
Veracyte is a U.S.-based molecular diagnostics company that develops and commercializes genomic tests used in cancer and other disease areas.
Last updated: 24/09/2026